Navigation Links
New evidence caffeine may slow Alzheimer's disease and other dementias, restore cognitive function
Date:5/17/2010

Amsterdam, The Netherlands, May 17, 2010 Although caffeine is the most widely consumed psychoactive drug worldwide, its potential beneficial effect for maintenance of proper brain functioning has only recently begun to be adequately appreciated. Substantial evidence from epidemiological studies and fundamental research in animal models suggests that caffeine may be protective against the cognitive decline seen in dementia and Alzheimer's disease (AD). A special supplement to the Journal of Alzheimer's Disease, "Therapeutic Opportunities for Caffeine in Alzheimer's Disease and Other Neurodegenerative Diseases," sheds new light on this topic and presents key findings.

Guest editors Alexandre de Mendona, Institute of Molecular Medicine and Faculty of Medicine, University of Lisbon, Portugal, and Rodrigo A. Cunha, Center for Neuroscience and Cell Biology of Coimbra and Faculty of Medicine, University of Coimbra, Portugal, have assembled a group of international experts to explore the effects of caffeine on the brain. The resulting collection of original studies conveys multiple perspectives on topics ranging from molecular targets of caffeine, neurophysiological modifications and adaptations, to the potential mechanisms underlying the behavioral and neuroprotective actions of caffeine in distinct brain pathologies.

"Epidemiological studies first revealed an inverse association between the chronic consumption of caffeine and the incidence of Parkinson's disease," according to Mendona and Cunha. "This was paralleled by animal studies of Parkinson's disease showing that caffeine prevented motor deficits as well as neurodegeneration "Later a few epidemiological studies showed that the consumption of moderate amounts of caffeine was inversely associated with the cognitive decline associated with aging as well as the incidence of Alzheimer's disease. Again, this was paralleled by animal studies showing that chronic caffeine administration prevented memory deterioration and neurodegeneration in animal models of aging and of Alzheimer's disease."

Key findings presented in "Therapeutic Opportunities for Caffeine in Alzheimer's Disease and Other Neurodegenerative Diseases":

  • Multiple beneficial effects of caffeine to normalize brain function and prevent its degeneration

  • Caffeine's neuroprotective profile and its ability to reduce amyloid-beta production

  • Caffeine as a candidate disease-modifying agent for Alzheimer's disease

  • Positive impact of caffeine on cognition and memory performance

  • Identification of adenosine A2A receptors as the main target for neuroprotection afforded by caffeine consumption

  • Confirmation of data through valuable meta-analyses presented

  • Epidemiological studies corroborated by meta-analysis suggesting that caffeine may be protective against Parkinson's disease

  • Several methodological issues must be solved before advancing to decisive clinical trials

Mendona and Cunha also observe that "the daily follow-up of patients with AD has taught us that improvement of daily living may be a more significant indicator of amelioration than slight improvements in objective measures of memory performance. One of the most prevalent complications of AD is depression of mood, and the recent observations that caffeine might be a mood normalizer are of particular interest."


'/>"/>

Contact: Astrid Engelen
a.engelen@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Related medicine news :

1. Aleres Dr. Michael Taitel Presents Compelling Evidence at IBI/NBCH Health & Productivity Forum that Wellness Programs Positively Impact Health & Productivity
2. New Scientific Studies Show Further Evidence of Avandia Dangers
3. More Evidence That Statins Cut Stroke Risk
4. Wiley-Blackwell launches new online medical reference tool -- Essential Evidence
5. Mayo Clinic Proceedings: Researchers find evidence of survival gains in bone marrow disease
6. Considering the evidence in health care
7. EBSCO Publishing and Zynx Health Expand Partnership for Integrated Access to Evidence-Based Content
8. Hayes Announces Appointment Of Dr Susan Levine To The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC)
9. Evidence-based care and outcomes improve at Get With The Guidelines-Stroke hospitals
10. Researchers find further evidence linking Epstein-Barr virus and risk of multiple sclerosis
11. More Evidence That Swings in Blood Pressure Raise Stroke Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... University of ... McDonald to the role of vice president of Student Engagement. In addition to ... facilities, athletics and student life areas. , “In the space of just one ...
(Date:4/28/2016)... ... April 28, 2016 , ... Greener Hydroponics is now offering a large ... used by professional organic farmers and nurseries according to Sales Manager Joe Steele who ... pots. Our goal is to offer wholesale level pricing and ultra-fast shipping for growers ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cognizin® ... VitaFoods 2016. , Nominated in the Healthy Ageing category, Cognizin® is being considered ... The Healthy Ageing division can include everything from antioxidants, lipids, proteins, and botanicals. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Collaboration Platform™ , today announced a new Residency Education & Collaboration Platform ... medical knowledge, educational resources, and a host of collaboration tools designed to ...
(Date:4/28/2016)... ... April 28, 2016 , ... Metabolic Nutrition today announced ... week’s 2016 Europa Games Get Fit and Sports Expo in Orlando, Florida. ... Orlando Expo coming up April 29-30, was selected as the perfect event to introduce ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... PUNE, India , April 28, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" is a report ... pipeline and helps strengthen R&D pipelines by identifying ... best-in-class products. Company Profiles discussed in ... Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen ...
(Date:4/27/2016)... Elekta today announced that its ... the focal point of seven scientific presentations at ESTRO ... Radiotherapy & Oncology, taking place April 29 - May ... system and a high-field MRI scanner with sophisticated software ... anatomy in real time. The MR-linac is designed to ...
(Date:4/27/2016)... 2016 Shire plc (LSE: SHP, NASDAQ: ... Chief Financial Officer, will present at the Deutsche Bank 41st ... on Wednesday, May 04, 2016, 10:00 am EDT (15:00 ... on the Presentations and Webcasts section of Shire,s Investor website ... will be available on this same website for approximately 90 ...
Breaking Medicine Technology: